Citius Pharmaceuticals, Inc. (CTXR): Total Assets
$130.94M
As of 2025-09-30
$142.26M
As of 2026-06-30
+4.7%
3-year compound annual growth
+24.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $130.94M | +12.2% | 2025-12-23, Balance as of period end |
| 2024-09-30 | $116.65M | +12.6% | 2025-12-23, Balance as of period end |
| 2023-09-30 | $103.61M | -9.1% | 2024-12-27, Balance as of period end |
| 2022-09-30 | $114.00M | -20.0% | 2023-12-29, Balance as of period end |
| 2021-09-30 | $142.43M | +225.4% | 2022-12-22, Balance as of period end |
| 2020-09-30 | $43.77M | +19.1% | 2021-12-15, Balance as of period end |
| 2019-09-30 | $36.75M | n/c | 2020-12-16, Balance as of period end |
| 2018-09-30 | $31.05M | +27.2% | 2019-12-16, Balance as of period end |
| 2017-09-30 | $24.42M | +11.2% | 2018-12-11, Balance as of period end |
| 2016-09-30 | $21.95M | n/m | 2017-12-13, Balance as of period end |
| 2015-09-30 | $741.5K | -52.4% | 2016-12-23, Balance as of period end |
| 2014-09-30 | $1.56M | n/a | 2015-12-14, Balance as of period end |
| 2013-09-30 | $0 | -100.0% | 2014-02-06, Balance as of period end |
| 2012-09-30 | $135 | -36.3% | 2014-02-06, Balance as of period end |
| 2011-09-30 | $212 | -91.5% | 2013-01-15, Balance as of period end |
| 2010-09-30 | $2.5K | n/a | 2012-01-13, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | 2025-09-30 | $130.94M | +12.2% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $131.44M | -35.1% |
| Acrivon Therapeutics, Inc. (ACRV) | 2025-12-31 | $129.72M | -34.0% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $127.04M | -38.7% |
| Seres Therapeutics, Inc. (MCRB) | 2025-12-31 | $138.19M | -1.2% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $138.29M | +43.5% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $140.72M | +133.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $119.59M | -44.3% |
Compare CTXR, SLN, ACRV, ZOMDF side by side · Screen every company in Pharmaceutical Preparations ↗